Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study

Table 1 Clinicopathological features of six lung adenocarcinoma patients with co-mutations of EGFR and ALK genes

Case	EGFR mutation	Gender	Age (yr)	Smoking history	TNM stage	Common metastatic sites
1#	19del	Female	55	No	IV	Bone
2#	19del/L858R	Female	39	No	IV	Liver, bone, adrenal gland
3#	20ins	Male	61	No	IIIA	None
4#	L858R	Female	57	No	IV	Bone
5#	L858R	Female	73	No	IV	Bone
6#	L861Q	Female	53	No	IV	Bone, brain

EGFR: Epidermal growth factor receptor; TNM: Tumor node metastasis.

Table 2 Follow-up data of six lung adenocarcinoma patients with co-mutations of EGFR and ALK genes

Case	1#	2#	3#	4#	5#	6#
1st line	Gefitinib1, 1 mo	GP, 1 course	Surgery	Gefitinib, 6 mo	Gefitinib, 3 mo	Erlotinib, 4 mo
2nd line	-	Gefitinib, 2 mo	GP2, 4 courses	-	-	Crizotinib3, 15 d
3rd line	-	GP, 1 course	Gefitinib, 2 mo	-	-	PC4, 2 courses
Status	Lost	Dead	CR	Lost	Dead	Dead
PFS	Unknown	2 mo	Unknown	6 mo	3 mo	4 mo

¹Gefitinib combined with radiotherapy.

²Sequential GP chemotherapy/4 courses and radiotherapy.

³Crizotinib combined with erlotinib.

⁴Bevacizumab combined with pemetrexed and carboplatin.

CR: Complete response; GP: Pemetrexed and carboplatin; PC: Pemetrexed and carboplatin; PFS: Progression-free survival.